<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A5E72F91-30E2-45E6-8D19-EDC197FF970A"><gtr:id>A5E72F91-30E2-45E6-8D19-EDC197FF970A</gtr:id><gtr:name>Monash University</gtr:name><gtr:address><gtr:line1>Monash University</gtr:line1><gtr:line2>Level 1, Chancellery Building D</gtr:line2><gtr:line3>26 Sports Walk, Wellington Road</gtr:line3><gtr:postCode>3800</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Australia</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:department>Cambridge Institute for Medical Research</gtr:department><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A5E72F91-30E2-45E6-8D19-EDC197FF970A"><gtr:id>A5E72F91-30E2-45E6-8D19-EDC197FF970A</gtr:id><gtr:name>Monash University</gtr:name><gtr:address><gtr:line1>Monash University</gtr:line1><gtr:line2>Level 1, Chancellery Building D</gtr:line2><gtr:line3>26 Sports Walk, Wellington Road</gtr:line3><gtr:postCode>3800</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Australia</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/29E28B0A-0B19-4075-B4EE-C67C6844C753"><gtr:id>29E28B0A-0B19-4075-B4EE-C67C6844C753</gtr:id><gtr:firstName>James</gtr:firstName><gtr:otherNames>Andrew</gtr:otherNames><gtr:surname>Huntington</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0801899"><gtr:id>388D0C66-F2CF-4D62-8DA7-D91309A66E26</gtr:id><gtr:title>Structural Basis of Serpin Polymerisation</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0801899</gtr:grantReference><gtr:abstractText>Many of the most prominent diseases of our age are cause by the self-association of proteins. These include Alzheimer?s, Huntington?s, Parkinson?s Diseases and the prion encephalopathies, such as Mad-Cow Disease, Scrapie and Creutzfeldt-Jakob Disease. These disorders have been classified as conformational diseases because the underlying protein alters its conformation to deposit stable aggregates either within or outside of cells. A family of proteins called the serpins can also self-associate to create stable intercellular deposits, through a mechanism called polymerisation, leading to dementia, cirrhosis and thrombosis, among other diseases. It is generally accepted that the design of successful treatment for any of the conformational diseases will require a detailed understanding of the conformational changes that lead to self-association. In this grant we investigate how serpins polymerise by using a combination of biochemical and structural techniques. We have recently solved a structure of a stable serpin dimer that revealed an unexpected, large-scale linkage and explained the infectivity of polymers and suggested how monomers become polymerogenic. We will determine if this mechanism underlies polymerisation of serpins in general and inside of living cells. The result will be a molecular picture of the monomeric and polymeric species to allow the rational design of drugs to slow, prevent or even reverse pathogenic protein association.</gtr:abstractText><gtr:technicalSummary>Ordered and stable protein association is the molecular basis behind several important diseases including Alzheimer?s, Huntington?s, Parkinson?s, and the prion encephalopathies, although the precise molecular mechanisms are unknown. A family of proteins known as the serpins also form stable intermolecular linkages resulting in protein accretion and diseases, such as dementia, cirrhosis and thrombosis. Because the serpins are structurally and functionally well characterised they have become the model for understanding the entire family of conformational diseases. Serpins utilise a thermodynamically-driven beta-sheet expansion mechanism for their function as protease inhibitors, and it is believed that a similar intermolecular beta-sheet expansion mechanism accounts for the stability of the serpin polymers. We have recently solved a crystal structure of a stable serpin dimer that revealed a large-scale domain swap including two strands of the central A beta-sheet (strands 4 and 5). In this grant we will determine if this unexpected mechanism is the molecular basis behind pathogenic serpin polymerisation by investigating the following hypotheses: i) linear serpin polymers exchange strands 5 and 4A, and that flexibility between protomers is conferred by some local unfolding; ii) the s4A/s5A domain swap we observe in our crystal structure is the general pathological mechanism behind serpin polymerisation and the resulting serpinopathies; and, iii) the polymerogenic monomeric state, M*, is formed by the release of strand 5 from beta-sheet A. We will employ a combination of biochemical and structural techniques using serpins antithrombin (AT) and alpha-1-antitrypsin (alpha1AT) to achieve the following three aims: 1) To determine the crystal structure of open AT polymers. 2) To determine if alpha1AT polymerises in cells using the s4A/s5A mechanism. 3) To determine the structure of the M* state. Successful completion of the aims will reveal the structural basis of serpin polymer formation and propagation, and allow the development of strategies to slow, prevent and even reverse serpin polymerisation.</gtr:technicalSummary><gtr:fund><gtr:end>2012-02-29</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-03-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>481852</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Monash University</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:department>Department of Biochemistry and Molecular Biology</gtr:department><gtr:description>domain swapping</gtr:description><gtr:id>D06E1CD4-CBAC-472B-B9E1-0FEEF66A1FAF</gtr:id><gtr:impact>One paper published in Embo Reports.</gtr:impact><gtr:outcomeId>UxxkhAarAym-1</gtr:outcomeId><gtr:partnerContribution>Contribution of a yeast expression system and associated methods. Intellectual input.</gtr:partnerContribution><gtr:piContribution>We expressed and purified multiple variants. Crystallised and solved structures. Analysed data and wrote paper.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Annual Report for Diamond</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>E943610D-F2F8-481F-AAED-182695AB65B0</gtr:id><gtr:impact>Some of our work on polymerisation was highlighted in the annual report.

NA</gtr:impact><gtr:outcomeId>hF4WgHu8E5a</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Policymakers/politicians</gtr:primaryAudience><gtr:url>http://www.diamond.ac.uk/Home/dms/Corporate/Annual-Reports/Diamond_Report_2010.pdf</gtr:url><gtr:year>2010</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>Z Factor Ltd</gtr:companyName><gtr:description>Z Factor Limited is a drug discovery company founded in 2015 to identify and develop therapeutic agents to treat alpha-1-antitrypsin deficiency. The company was created by Index Ventures in partnership with the University of Cambridge. 

Alpha-1-antitrypsin deficiency is a genetic disorder that affects 1 in 2,000 people of European descent. The most common disease-causing mutation is the Z-variant. Z alpha-1-antitrypsin is fully functional when secreted, but most of the protein misfolds and accumulates in liver cells as polymers. People suffering from alpha-1-antitrypsin deficiency can present either early in life or late in life with liver cirrhosis. However, the most common manifestation of alpha-1-antitrypsin deficiency is emphysema, generally diagnosed in midlife. Current treatments are limited to lung or liver transplantation and augmentation therapy, whereby protein purified from normal blood is repeatedly administered via weekly intravenous infusions. 

Z Factor is exploiting insight into the structure of the Z-variant of alpha-1-antitrypsin derived from research conducted in the laboratory of Professor Jim Huntington at the University of Cambridge. Z Factor is therefore uniquely placed to design and develop novel therapeutic agents to correct the misfolding of the Z variant and to thereby address an important and unmet medical need.</gtr:description><gtr:id>25D72229-DA1F-49F2-9CF9-09F6F2B680E9</gtr:id><gtr:impact>The company has successfully discovered several drug-like compounds that rescue Z antitrypsin folding in in vivo models, and has passed from a seed round of &amp;pound;1.1M to a &amp;pound;7M Series A completed in March 2017.</gtr:impact><gtr:outcomeId>56e00cb7790979.31790262</gtr:outcomeId><gtr:url>http://zfactor.co.uk/</gtr:url><gtr:yearCompanyFormed>2015</gtr:yearCompanyFormed></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication><gtr:id>F19B540C-1037-4CEA-9675-47AA580CBC01</gtr:id><gtr:title>Molecular basis of a1-antitrypsin deficiency revealed by the structure of a domain-swapped trimer.</gtr:title><gtr:parentPublicationTitle>EMBO reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a4ff010a87dc5eea5b8f193fa66f291c"><gtr:id>a4ff010a87dc5eea5b8f193fa66f291c</gtr:id><gtr:otherNames>Yamasaki M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1469-221X</gtr:issn><gtr:outcomeId>AGFNeQGPDjw</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C33E405B-16D4-428F-AA9B-1CDAEE52C4A3</gtr:id><gtr:title>Serpin polymerization in vitro.</gtr:title><gtr:parentPublicationTitle>Methods in enzymology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7823177e5f34aa3434ec7d9a3574641e"><gtr:id>7823177e5f34aa3434ec7d9a3574641e</gtr:id><gtr:otherNames>Huntington JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0076-6879</gtr:issn><gtr:outcomeId>pNWdQTAfkdb</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>38B0F10B-3315-4523-9147-7B4AC565531F</gtr:id><gtr:title>Molecular contortionism - on the physical limits of serpin 'loop-sheet' polymers.</gtr:title><gtr:parentPublicationTitle>Biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7823177e5f34aa3434ec7d9a3574641e"><gtr:id>7823177e5f34aa3434ec7d9a3574641e</gtr:id><gtr:otherNames>Huntington JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1431-6730</gtr:issn><gtr:outcomeId>shUNb8KXii8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>476861AB-BEDB-4724-8284-C00542ED0E09</gtr:id><gtr:title>Type II antithrombin deficiency caused by a large in-frame insertion: structural, functional and pathological relevance.</gtr:title><gtr:parentPublicationTitle>Journal of thrombosis and haemostasis : JTH</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/67777712ba215bf7b83f12faae10638a"><gtr:id>67777712ba215bf7b83f12faae10638a</gtr:id><gtr:otherNames>Mart?nez-Mart?nez I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1538-7836</gtr:issn><gtr:outcomeId>pm_12842_22_22758787</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8ABD217D-1F1E-47B2-B6D9-242CDE0418A9</gtr:id><gtr:title>New insight into serpin polymerization and aggregation.</gtr:title><gtr:parentPublicationTitle>Prion</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7823177e5f34aa3434ec7d9a3574641e"><gtr:id>7823177e5f34aa3434ec7d9a3574641e</gtr:id><gtr:otherNames>Huntington JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1933-6896</gtr:issn><gtr:outcomeId>585d4e25007ba2.18110626</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5BA23DF6-5772-4094-BB7C-E75F3A875521</gtr:id><gtr:title>Loop-sheet mechanism of serpin polymerization tested by reactive center loop mutations.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a4ff010a87dc5eea5b8f193fa66f291c"><gtr:id>a4ff010a87dc5eea5b8f193fa66f291c</gtr:id><gtr:otherNames>Yamasaki M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>Pa4WQ9FLVm3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>896DDBC3-A8D9-4A03-A5DD-2A4058933DC5</gtr:id><gtr:title>Crystal structure of a stable dimer reveals the molecular basis of serpin polymerization.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a4ff010a87dc5eea5b8f193fa66f291c"><gtr:id>a4ff010a87dc5eea5b8f193fa66f291c</gtr:id><gtr:otherNames>Yamasaki M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>23AE0C65AE3</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0801899</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>